BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29645093)

  • 1. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
    Smith SM; Godfrey J; Ahn KW; DiGilio A; Ahmed S; Agrawal V; Bachanova V; Bacher U; Bashey A; Bolaños-Meade J; Cairo M; Chen A; Chhabra S; Copelan E; Dahi PB; Aljurf M; Farooq U; Ganguly S; Hertzberg M; Holmberg L; Inwards D; Kanate AS; Karmali R; Kenkre VP; Kharfan-Dabaja MA; Klein A; Lazarus HM; Mei M; Mussetti A; Nishihori T; Ramakrishnan Geethakumari P; Saad A; Savani BN; Schouten HC; Shah N; Urbano-Ispizua A; Vij R; Vose J; Sureda A; Hamadani M
    Cancer; 2018 Jun; 124(12):2541-2551. PubMed ID: 29645093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
    Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?
    Hamadani M; Horowitz MM
    J Oncol Pract; 2017 Dec; 13(12):798-806. PubMed ID: 29232542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
    Epperla N; Ahn KW; Armand P; Jaglowski S; Ahmed S; Kenkre VP; Savani B; Jagasia M; Shah NN; Fenske TS; Sureda A; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):78-85. PubMed ID: 29032272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.
    Klyuchnikov E; Bacher U; Woo Ahn K; Carreras J; Kröger NM; Hari PN; Ku GH; Ayala E; Chen AI; Chen YB; Cohen JB; Freytes CO; Gale RP; Kamble RT; Kharfan-Dabaja MA; Lazarus HM; Martino R; Mussetti A; Savani BN; Schouten HC; Usmani SZ; Wiernik PH; Wirk B; Smith SM; Sureda A; Hamadani M
    Bone Marrow Transplant; 2016 Jan; 51(1):58-66. PubMed ID: 26437062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors.
    Guru Murthy GS; Kim S; Hu ZH; Estrada-Merly N; Abid MB; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bredeson C; Cahn JY; Cerny J; Diaz Perez MA; Farhadfar N; Gale RP; Ganguly S; Gergis U; Hildebrandt GC; Grunwald MR; Hashmi S; Hossain NM; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Hamilton BK; Lazarus HM; Liesveld J; Litzow M; Marks DI; Murthy HS; Nathan S; Nazha A; Nishihori T; Patel SS; Pawarode A; Rizzieri D; Savani B; Seo S; Solh M; Ustun C; van der Poel M; Verdonck LF; Vij R; Wirk B; Oran B; Nakamura R; Scott B; Saber W
    JAMA Oncol; 2022 Mar; 8(3):404-411. PubMed ID: 35024768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Giebel S; Labopin M; Houhou M; Caillot D; Finke J; Blaise D; Fegueux N; Ethell M; Cornelissen JJ; Forcade E; Yakoub-Agha I; Lussana F; Maertens J; Bourhis JH; Jindra P; Gorin NC; Nagler A; Mohty M
    Bone Marrow Transplant; 2023 Apr; 58(4):393-400. PubMed ID: 36611097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.
    Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Laport GG; Montoto S; Maloney DG; Lazarus HM
    Biol Blood Marrow Transplant; 2013 May; 19(5):746-53. PubMed ID: 23380340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.
    Wirk B; Fenske TS; Hamadani M; Zhang MJ; Hu ZH; Akpek G; Aljurf MD; Armand P; Ayala E; Bachanova V; Bolwell B; Cairo MS; Cashen A; Chen YB; Costa LJ; Farhan S; Freytes CO; Gajewski JL; Gibson J; Hale GA; Holmberg LA; Hsu JW; Inwards DJ; Kamble RT; Maharaj D; Maziarz RT; Munker R; Nath R; Reddy NM; Reeder CB; Rizzieri DA; Sauter CS; Savani BN; Schouten HC; Sureda A; Vose JM; Waller EK; Wiernik PH; Gale RP; Burns LJ; Saber W
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):951-9. PubMed ID: 24641828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.
    Casulo C; Friedberg JW; Ahn KW; Flowers C; DiGilio A; Smith SM; Ahmed S; Inwards D; Aljurf M; Chen AI; Choe H; Cohen J; Copelan E; Farooq U; Fenske TS; Freytes C; Gaballa S; Ganguly S; Jethava Y; Kamble RT; Kenkre VP; Lazarus H; Lazaryan A; Olsson RF; Rezvani AR; Rizzieri D; Seo S; Shah GL; Shah N; Solh M; Sureda A; William B; Cumpston A; Zelenetz AD; Link BK; Hamadani M
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1163-1171. PubMed ID: 29242111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study.
    Kharfan-Dabaja MA; Al Malki MM; Deotare U; Raj RV; El-Jurdi N; Majhail N; Cherry MA; Bashir Q; Darrah J; Nishihori T; Sibai H; Hamadani M; de Lima M; Gerds AT; Selby G; Qazilbash MH; Forman SJ; Ayala E; Lipton JH; Hari PN; Muzzafar T; Zhang L; Olteanu H; Perkins J; Sokol L; Kumar A; Ahmed S
    Br J Haematol; 2017 Dec; 179(5):781-789. PubMed ID: 28980314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
    Epperla N; Ahn KW; Litovich C; Ahmed S; Battiwalla M; Cohen JB; Dahi P; Farhadfar N; Farooq U; Freytes CO; Ghosh N; Haverkos B; Herrera A; Hertzberg M; Hildebrandt G; Inwards D; Kharfan-Dabaja MA; Khimani F; Lazarus H; Lazaryan A; Lekakis L; Murthy H; Nathan S; Nishihori T; Pawarode A; Prestidge T; Ramakrishnan P; Rezvani AR; Romee R; Shah NN; Sureda A; Fenske TS; Hamadani M
    J Hematol Oncol; 2019 Jan; 12(1):6. PubMed ID: 30630534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
    Dreger P; Sureda A; Ahn KW; Eapen M; Litovich C; Finel H; Boumendil A; Gopal A; Herrera AF; Schmid C; Diez-Martin JL; Fuchs E; Bolaños-Meade J; Gooptu M; Al Malki MM; Castagna L; Ciurea SO; Dominietto A; Blaise D; Ciceri F; Tischer J; Corradini P; Montoto S; Robinson S; Gülbas Z; Hamadani M
    Blood Adv; 2019 Feb; 3(3):360-369. PubMed ID: 30723110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
    Ahmed S; Kanakry JA; Ahn KW; Litovich C; Abdel-Azim H; Aljurf M; Bacher VU; Bejanyan N; Cohen JB; Farooq U; Fuchs EJ; Bolaños-Meade J; Ghosh N; Herrera AF; Hossain NM; Inwards D; Kanate AS; Martino R; Munshi PN; Murthy H; Mussetti A; Nieto Y; Perales MA; Romee R; Savani BN; Seo S; Wirk B; Yared JA; Sureda A; Fenske TS; Hamadani M
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1859-1868. PubMed ID: 31132455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
    Jagadeesh D; Majhail NS; He Y; Ahn KW; Litovich C; Ahmed S; Aljurf M; Bacher U; Badawy SM; Bejanyan N; Cairo M; Cerny J; Epperla N; Farhadfar N; Freytes CO; Gale RP; Haverkos B; Hossain N; Inwards D; Kamble RT; Kenkre VP; Lazarus HM; Lazaryan A; Lekakis L; Mei M; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Ramakrishnan Geethakumari P; Savani BN; Yared JA; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
    Cancer; 2020 May; 126(10):2279-2287. PubMed ID: 32049359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.
    Björkstrand B; Iacobelli S; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Musto P; Beksac M; Bosi A; Milone G; Corradini P; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Gahrton G
    J Clin Oncol; 2011 Aug; 29(22):3016-22. PubMed ID: 21730266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics.
    Hamadani M; Ngoya M; Sureda A; Bashir Q; Litovich CA; Finel H; Chen Y; Boumendil A; Zain J; Castagna L; Cashen AF; Blaise D; Shadman M; Pastano R; Khimani F; Arat M; Dietrich S; Schmitz N; Glass B; Kharfan-Dabaja MA; Corradini P; Sauter CS; Montoto S; Kwon M; Herrera AF; Dreger P
    Blood Adv; 2022 Feb; 6(3):920-930. PubMed ID: 34861680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.